Kingdom of Saudi Arabia （KSA）
Country Information:
Capital
Riyadh
Main city
Jeddah, Mecca, Medina, Al-Ahsa, Taif, Dammam
Primary Ports
Dammam, Jeddah, Jubail
Populace
The complete populace of Saudi Arabia in 2020 is 34.8139 million.
The male populace is 20.1 million, representing 57.73%
of the complete populace; the female populace is 14.7139 million, representing
42.27% of the absolute populace.
The metropolitan populace is 28.8078 million and the
provincial populace is 5.4607 million. The urbanization rate is 84.07%.
The populace matured 0-14 represented 24.87%, the
populace matured 15-64 represented 71.72%, and the populace matured 65 or more represented
3.41%.
NCD fatality rate (year 2019)
1 Ischemic coronary illness
2 Stroke
3 Chronic kidney infection
4 Cirrhosis
5 Diabetes
6 COPD
7 Congenital imperfections
8 Alzheimer's disease
9 Colorectal cancer
10 Lung cancer
Financial
GDP（2020） 700.118 billion
Gross domestic product Growth Rate until
2020）：CAGR - 4.11%
Currency： Saudi Riyal
Trade Value in USD: 1000 Saudi Riyal approaches 266.73 US Dollar
Public Economic Development Strategy
"Saudi Arabia Vision 2030"
Gulf Cooperation Council (GCC)
The Gulf Cooperation Council is a global association
comprising of Saudi Arabia, Kuwait, United Arab Emirates, Qatar, Bahrain and
Oman. Starting around 2014, these nations have together planned a medication
value coordination technique to normalize drug costs in the district and lessen
numerous administrative hindrances. One case is the international alliance
among GCC and India, which has incited Indian drug organizations to
additionally enter the Middle East market. Simultaneously, because of the great
normal buying power and a culture of doubt of low-estimated items delivered
abroad, API imports may ultimately happen for limited creation.
Status of the drug market
Saudi Arabia is the most appealing business sector for
global drug organizations in the Middle East. On account of the "Saudi
Vision 2030", the extension of Saudi assembling is supported, which is a
decent sign for nearby Saudi organizations and organizations in the Gulf nations.
Nonetheless, patent approval and severe regulatory
frameworks stay significant issues for unfamiliar examination based drug
organizations.
Saudi Arabia's drawn out objective is to create 40% of
the medication locally.
Innovative Drug Market
Because of the nearby inclination for marked
medications, Saudi Arabia's market is overwhelmed by unfamiliar drug-makers and
homegrown assembling is little. Driving nearby players incorporate Saudi
Pharmaceutical Industries and Medical Appliances Company (SPIMACO), Tabuk
Pharmaceutical Manufacturing, Jamjoom Pharma and Saudi Arabian Japan
Pharmaceutical Company (SAJA). Most medications are imported from developed
nations, including Switzerland, Germany, France, the US and the UK.
Multinationals are generally present, including Novartis, Pfizer, Bayer,
Bristol-Myers Squibb, Roche and Eli Lilly; yet just GSK and Sanofi produce
locally. All things considered, numerous worldwide organizations have picked
agreement fabricating with Saudi Arabian drug-makers to save costs.
Conventional Drug Market
The public authority is empowering the conventional
medication market in Saudi Arabia, supplanting licensed medications with
nonexclusive medications to control costs. Nonexclusive medications will
develop at a quicker rate in the close and long haul because of worked on
administrative principles in the Kingdom. Significant obstacles incorporate
prescribers' inclination for protected meds and the generally high per capita
expenditure of the populace on prescriptions, yet this will likewise set the
way for marked generics to grow.
Nonexclusive medications are at present esteemed at
$2.9 billion (35% of the absolute market in 2019) and are relied upon to
develop at a CAGR of 8.1% throughout the following five years, coming to $4.4
billion of every 2024, or 39% of the all-out market.
The country's neighborhood nonexclusive medication
industry is powered by government support. Neighborhood nonexclusive medication
creators will profit from nearer local incorporation plans and more noteworthy
accentuation on drugs delivered inside the GCC. Endeavors to wean the district
from over-dependence on imported medications.
Saudi Arabia's API depends on imports.
Market Volume
In 2018, the Saudi drug market developed at a CAGR of
almost 5% to reach roughly $8.2 billion.
In 2019, the Saudi drug market developed by 5.2% from
$8.3 billion to $8.8 billion before the finish of 2020.
It is relied upon to develop at a build yearly
development pace of 5.4% to $10.89 billion by 2024.
Patented medication spending represented 54.4% of the
market, with a market worth of US$4.5 billion being the biggest drug market
altogether, yet positioned seventh in the Gulf district as far according to
capita drug expenditure of US$242. Conventional medications represent 35% of
the market, with a market worth of $2.9 billion. OTC medications represented
11%, with a market worth of $900 million. (2019)
Enrolled Organization:
Saudi Food and Drug Authority
https://www.Sfda.Gov.Sa/en
General registration time: 6-18 months
Registration requirements [File format]: e-CTD
Plant Inspection: yes
Pharmaceutical trade
Saudi Arabia's Vision 2030 and National Transformation
Plan will urge the country to extend its homegrown drug industry. This will
lessen dependence on imported conventional medications while giving commodity
chances to import-subordinate adjoining nations.
The nation imported $5.9 billion of every 2019. Imports
are conjecture to reach $6.6 billion by 2023, developing at a CAGR of 4.4%.
Import appropriation is altogether constrained by Saudi Arabian organizations,
drove by the private area Banaja Saudi Import Company and the public authority
obtainment unit NUPCO.
Nearby predispositions against neighborhood and local makers,
local coordination and more prominent aggregate dealing among GCC nations are
relied upon to assist with invigorating neighborhood creation and lift trades.
Top Ten Corporation
(Deals Value USD Millions MAT Q1 2019)
1 PFIZER 644
2 SANOFI 535
3 NOVARTIS 420
4 TABUK 410
5 SPIMACO 385
6 GSK 375
7 HIKMA PHARMA 338
8 NOVO NORDISK 312
9 MSD 294
10 ASTRAZENECA 240
Quickest growing Corporations
(MAT Q1 2019, USD Millions, Previous Period Growth
(PPG))
1 MSD 294,43%
2 HIKMA PHARMA 338,41%
3 MECP 125,37%
4 AMGEN 110,31%
5 SANOFI 535,28%
6 LILLY 132,26%
7 ASTRAZENICA 240,21%
8 J&J 188,20%
9 ALLERGAN 93,16%
10 SERVIER 70,13%
